Story

Ardelyx Stock Plunges on Q2 Earnings Miss, Slashed Revenue Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
Ardelyx Stock Plunges on Q2 Earnings Miss, Slashed Revenue Guidance
Text size
Background

Shares of Ardelyx (NASDAQ: ARDX) plunged 16.0% in pre-market trading after the company announced second-quarter 2026 financial results that fell short of Wall Street expectations and issued a material reduction to its full-year revenue outlook.

Disappointing Quarterly Results

Ardelyx reported total product revenue of $118.1 million for the second quarter, an increase of 31% year-over-year. However, this figure missed the consensus analyst forecast of approximately $125 million. The company's revenue was driven by $86.2 million from its irritable bowel syndrome drug IBSRELA and $31.9 million from its kidney disease treatment XPHOZAH.

On the bottom line, the company posted a net loss of $16.7 million, or $0.07 per share. This was wider than the average analyst estimate, which had projected a smaller loss of $0.04 per share.

Guidance Cut Rattles Investors

The most significant factor driving the stock's decline was a downward revision of its sales forecast. Ardelyx lowered its full-year 2026 revenue guidance for IBSRELA to a range of $350 million to $370 million. The company attributed the cut to "more stringent payer prior authorizations and step edits," which it said are slowing the rate of new patient prescriptions despite record demand and refills.

Sample IUX Markets – In-articleAd

Further adding to investor uncertainty, Ardelyx withdrew its long-term revenue target of $750 million for XPHOZAH. While it reiterated its 2026 guidance of $110 million to $120 million for the drug, the company stated it needs to reassess the market's long-term potential following policy changes related to dialysis payments.

Context and Market Reaction

The sharp sell-off was company-specific, occurring while the broader market was modestly positive. The pressure on Ardelyx shares reflects investor concern over the newly identified commercial headwinds for IBSRELA and the increased uncertainty surrounding the long-term growth trajectory of XPHOZAH.

CEO Mike Raab acknowledged the issues, stating, "We do understand the challenges that we are facing, and we’ve taken decisive action to address them." Despite the near-term setbacks, the company ended the quarter with $281.8 million in cash and maintained its expectation of achieving profitability in 2027.

Read next

More on Stocks
Back to latest news

LATEST